Ocuphire Pharma, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Medical Advisory Board
  • Product Pipeline
    • Overview
    • Nyxol
    • APX3330
    • APX2009
    • Posters and Publications
  • Clinical Trials
    • Overview
    • MIRA-2: Reversal of Mydriasis Phase 3 Clinical Trial for Nyxol Recruiting Completed
    • LYNX-1: Dim Light Vision Disturbance Phase 3 Clinical Trial for Nyxol Recruiting
    • VEGA-1: Presbyopia Phase 2 Clinical Trial for Nyxol with Low-Dose Pilocarpine Recruiting
    • ZETA-1: Diabetic Retinopathy Phase 2 Clinical Trial for APX3330 Recruiting
  • Partnerships
  • News & Media
    • Press Releases
    • Presentations
    • Events
    • Ocuphire in the News
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Events
    • Email Alerts
  • Company Information
    • Overview
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Financial Information
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Corporate Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • Events
  • Email Alerts

Ocuphire Pharma Raises Over $5 Million to Complete Multiple Late Phase 2 Clinical Trials

Jul 22, 2019

Rexahn Announces Move to Nasdaq

May 28, 2019

Rexahn Pharmaceuticals Reports First Quarter 2019 Financial Results

May 13, 2019

Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China

Apr 16, 2019

Rexahn Effects 1-for-12 Reverse Stock Split

Apr 12, 2019

Rexahn Announces Reverse Stock Split

Apr 10, 2019

Rexahn Announces Multiple Presentations at the 2019 American Association for Cancer Research Annual Meeting

Mar 27, 2019

Rexahn Pharmaceuticals Reports 2018 Financial Results

Mar 8, 2019

Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE® in First-line Metastatic Pancreatic Cancer Patients

Mar 4, 2019

Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors

Mar 1, 2019
RSS
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...33
    Ocuphire Pharma, Inc.
    © Ocuphire Pharma, Inc. All rights reserved. Privacy Policy Disclaimer Sitemap Terms of Use